Extreme insulin resistance in ataxia telangiectasia: defect in affinity of insulin receptors. 1978

R S Bar, and W R Levis, and M M Rechler, and L C Harrison, and C Siebert, and J Podskalny, and J Roth, and M Muggeo

The syndrome of ataxia telangiectasia is associated with glucose intolerance and insulin resistance. We examined the status of insulin receptors on circulating monocytes and on cultured fibroblasts from two siblings with ataxia telangiectasia and severe insulin resistance. 125I-insulin binding to monocytes of the two patients consistently demonstrated an 80 to 85 per cent decrease in receptor affinity. In contrast, the defect in receptor affinity was not expressed on the patients' cultured fibroblasts or on monocytes or fibroblasts obtained from unaffected family members. Whole plasma and immunoglobulin-enriched fractions of plasma from the patients inhibited the normal binding of insulin to its receptors on cultured human lymphocytes (IM -9 line) and on human placental membranes. We conclude that the insulin resistance in the two siblings with ataxia telangiectasia was associated with defects in the affinity of the receptors for insulin, probably caused by circulating inhibitors of insulin binding.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007333 Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. Insulin Sensitivity,Resistance, Insulin,Sensitivity, Insulin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D011972 Receptor, Insulin A cell surface receptor for INSULIN. It comprises a tetramer of two alpha and two beta subunits which are derived from cleavage of a single precursor protein. The receptor contains an intrinsic TYROSINE KINASE domain that is located within the beta subunit. Activation of the receptor by INSULIN results in numerous metabolic changes including increased uptake of GLUCOSE into the liver, muscle, and ADIPOSE TISSUE. Insulin Receptor,Insulin Receptor Protein-Tyrosine Kinase,Insulin Receptor alpha Subunit,Insulin Receptor beta Subunit,Insulin Receptor alpha Chain,Insulin Receptor beta Chain,Insulin-Dependent Tyrosine Protein Kinase,Receptors, Insulin,Insulin Receptor Protein Tyrosine Kinase,Insulin Receptors
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D005260 Female Females
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral

Related Publications

R S Bar, and W R Levis, and M M Rechler, and L C Harrison, and C Siebert, and J Podskalny, and J Roth, and M Muggeo
November 1978, The Journal of pediatrics,
R S Bar, and W R Levis, and M M Rechler, and L C Harrison, and C Siebert, and J Podskalny, and J Roth, and M Muggeo
January 1997, Annual review of immunology,
R S Bar, and W R Levis, and M M Rechler, and L C Harrison, and C Siebert, and J Podskalny, and J Roth, and M Muggeo
July 1972, Pediatrics,
R S Bar, and W R Levis, and M M Rechler, and L C Harrison, and C Siebert, and J Podskalny, and J Roth, and M Muggeo
September 1985, Nihon Naibunpi Gakkai zasshi,
R S Bar, and W R Levis, and M M Rechler, and L C Harrison, and C Siebert, and J Podskalny, and J Roth, and M Muggeo
June 1983, The Journal of clinical investigation,
R S Bar, and W R Levis, and M M Rechler, and L C Harrison, and C Siebert, and J Podskalny, and J Roth, and M Muggeo
November 1991, Clinical immunology and immunopathology,
R S Bar, and W R Levis, and M M Rechler, and L C Harrison, and C Siebert, and J Podskalny, and J Roth, and M Muggeo
September 1996, Oncogene,
R S Bar, and W R Levis, and M M Rechler, and L C Harrison, and C Siebert, and J Podskalny, and J Roth, and M Muggeo
October 1990, The New England journal of medicine,
R S Bar, and W R Levis, and M M Rechler, and L C Harrison, and C Siebert, and J Podskalny, and J Roth, and M Muggeo
December 1982, The Journal of clinical endocrinology and metabolism,
R S Bar, and W R Levis, and M M Rechler, and L C Harrison, and C Siebert, and J Podskalny, and J Roth, and M Muggeo
December 1994, International journal of radiation biology,
Copied contents to your clipboard!